Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win

Zacks10-17

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476921108?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vEcnkVRWY1.AKxOmZ2RQiQ--~B/aD00MTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9080893d83d7b91adebaa73de0275743","is_english":true,"pubTime":"2024-10-17 01:47","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476921108","market":"us","top_or_hot":-1,"title":"Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win","media":"Zacks","content":"<div>\n<p>In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...</p>\n\n<a href=\"https://finance.yahoo.com/news/inside-booming-obesity-drug-market-174700789.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInside the Booming Obesity Drug Market: Weight Loss ETFs to Win\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 01:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/inside-booming-obesity-drug-market-174700789.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global...</p>\n\n<a href=\"https://finance.yahoo.com/news/inside-booming-obesity-drug-market-174700789.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/inside-booming-obesity-drug-market-174700789.html","article_id":"2476921108","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vEcnkVRWY1.AKxOmZ2RQiQ--~B/aD00MTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9080893d83d7b91adebaa73de0275743"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476921108","pubTimestamp":1729100820,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035,per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.Two companies — Eli Lilly LLY and Novo Nordisk NVO — dominate the weight-loss drug market and their stocks have surged in the recent past due to soaring demand for their products. There are a few other ways to play this market. Exchange-traded funds  are the best way","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","HRTS":"Tema Cardiovascular and Metabolics ETF","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","NVO":"诺和诺德","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0882574055.USD":"富达全球健康医疗A ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4550":"红杉资本持仓","LLY":"礼来","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0882574139.USD":"富达环球消费行业基金A ACC","PPH":"VanEck Pharmaceutical ETF","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","FDN":"First Trust Dow Jones Internet I","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4534":"瑞士信贷持仓","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","BK4516":"特朗普概念","BK4007":"制药","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"蓬勃发展的肥胖药物市场内幕：减肥ETF获胜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THNR":1,"PPH":1,"HRTS":1,"NVO":0.95,"FDN":0.9,"LLY":0.9},"content_text":"In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.\nAs the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.\nTwo companies — Eli Lilly LLY and Novo Nordisk NVO — dominate the weight-loss drug market and their stocks have surged in the recent past due to soaring demand for their products. There are a few other ways to play this market. Exchange-traded funds (ETFs) are the best ways to access this evolving market.\nVanEck Pharmaceutical ETF PPH, Obesity & Cardiometabolic ETF HRTS, and Amplify Weight Loss Drug & Treatment ETF THNR are the ETFs to play this emerging market.\nWhat Are GLP-1 Receptor Agonists?\nGLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%. GLP-1 (Glucagon-Like Peptide-1) receptor agonists, including semaglutide, are marketed under names like Ozempic and Wegovy.\nOzempic and Wegovy: Market Leaders\nNovo Nordisk’s Ozempic and Wegovy are at the forefront of this market, particularly in addressing the obesity epidemic. Initially approved for Type 2 diabetes, Ozempic quickly gained off-label popularity for its significant weight loss effects. Wegovy, also developed by Novo Nordisk, is specifically designed for weight loss and received FDA approval for this purpose.\nHow Crowded Is the Weight Loss Drug Market?\nExperts predict that GLP-1 drugs could become blockbuster products with multi-billion-dollar sales potential. Eli Lilly and Novo Nordisk, too, could face stiff competition. Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs, as quoted on CNBC.\nCEO Adam Steensberg indicated early-stage trial results of its GLP-1 treatment in an interview with CNBC, but said that it is the company’s separate obesity drug candidate — Petrelintide, a long-acting amylin analog — that could set it apart in the weight-loss drug segment.\nNote that Amylin mimics a different hunger-regulating hormone. As a result, Petrelintide could prove to be an alternative for users who are intolerant of GLP-1s. Plus, last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide.\nSan Diego-based Viking Therapeutics emerged as a competitor in the weight loss drug market in February after revealing promising data from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection. In March, the company disclosed plans to test an oral tablet version after a small stage trial indicated weight loss as high as 3.3%, as quoted on Forbes.\nThe Forbes article went on to point out that Terns Pharmaceuticals is developing an oral weight loss drug targeting the GLP-1 hormone and expects to release 28-day data on weight loss from an early-stage trial in the second half of 2024.\nSan Francisco startup Structure Therapeutics is also developing an oral, once-daily GLP-1 drug named GSBR-1290. The drug topped Wall Street’s expectations in June when a mid-stage study revealed an average weight loss of around 6%, and the company announced plans to start another mid-stage trial toward the end of this year, per Forbes.\nBiotech giant Amgen scrapped plans for an experimental weight loss pill in May but is still looking for a share of the market with MariTide, a monthly injection that is taken less frequently than popular weekly treatments from Lilly and Novo and notably appears to help some patients maintain weight loss, per a Forbes article.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nVanEck Pharmaceutical ETF (PPH): ETF Research Reports\nTema GLP-1, Obesity & Cardiometabolic ETF (HRTS): ETF Research Reports\nAmplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476921108"}